Generic Name: glucagon
Brand Name: Baqsimi
Manufacturer: Eli Lilly Canada Inc.
Indications: Severe hypoglycemic reactions
Manufacturer Requested Reimbursement Criteria1: For the treatment of severe hypoglycemic reactions which may occur in the management of insulin treated patients with diabetes mellitus, when impaired consciousness precludes oral carbohydrates.
Submission Type: New
Project Status: Active
Companion Diagnostics: No
Date Recommendation Issued: January 22, 2020
Recommendation Type: Reimburse with clinical criteria and/or conditions
Fee Schedule: Schedule A
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Key Milestones2 | |
|---|---|
| Call for patient input posted | June 25, 2019 |
| Patient group input closed | August 15, 2019 |
| Clarification: - Patient input submission received from Diabetes Canada and Type 1 Together/Ensemble | |
| Patient input summary sent for review to patient input groups | September 12, 2019 |
| Patient group comments on input summary closed | September 19, 2019 |
| Clarification: - Patient input summary feedback received | |
| Submission received | July 24, 2019 |
| Submission accepted | August 08, 2019 |
| Review initiated | August 09, 2019 |
| Draft CADTH review report(s) sent to sponsor | October 24, 2019 |
| Comments from sponsor on draft CADTH review report(s) received | November 04, 2019 |
| CADTH review team's comments on draft CADTH review report(s) sent to sponsor | November 29, 2019 |
| Canadian Drug Expert Committee (CDEC) meeting | December 11, 2019 |
| CDEC recommendation sent to sponsor and drug plans | December 24, 2019 |
| CDEC Final Recommendation & CADTH review report(s) issued to sponsor and drug plans | January 22, 2020 |
| CDEC Final Recommendation posted | January 24, 2020 |
| Redaction requests from sponsor on draft CADTH review report(s) received | February 05, 2020 |
| Redacted CADTH review report(s) sent to sponsor and drug plans | February 18, 2020 |
| Validation of redacted CADTH review report(s) received | February 25, 2020 |
| Final CADTH review report(s) posted | - |